Keryx Biopharmaceuticals, Inc. (KERX) Forms $5.08 Double Bottom; Horace Mann Educators (HMN) Had 1 Analysts Last Week

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Logo

Keryx Biopharmaceuticals, Inc. (KERX) formed double bottom with $4.67 target or 8.00% below today’s $5.08 share price. Keryx Biopharmaceuticals, Inc. (KERX) has $612.27M valuation. The stock increased 0.40% or $0.02 during the last trading session, reaching $5.08. About 742,758 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 18.22% since June 14, 2017 and is downtrending. It has underperformed by 30.79% the S&P500. Some Historical KERX News: ; 04/04/2018 – Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency; 04/04/2018 – Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology; 13/03/2018 – Keryx Closes Below 50-Day Moving Average: Technicals; 11/04/2018 – Keryx Closes Above 50-Day Moving Average: Technicals; 30/04/2018 – Keryx Biopharm Announces Gregory Madison Resigned as Pres, CEO and From Board of Directors; 08/05/2018 – The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes it; 30/04/2018 – Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue; 24/05/2018 – Keryx Presenting at ERA-EDTA Annual Congress 2018 Tomorrow; 11/04/2018 – Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation; 08/05/2018 – The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia lndication in the Pre-Dialysis Setting

Among 4 analysts covering Horace Mann Educators Corp (NYSE:HMN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Horace Mann Educators Corp had 11 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Thursday, August 17 by Keefe Bruyette & Woods. The rating was upgraded by Keefe Bruyette & Woods to “Hold” on Tuesday, September 5. On Monday, May 29 the stock rating was maintained by Wood with “Sell”. The firm has “” rating given on Tuesday, April 11 by Wood. Keefe Bruyette & Woods maintained Horace Mann Educators Corporation (NYSE:HMN) rating on Monday, December 4. Keefe Bruyette & Woods has “Hold” rating and $45.0 target. On Tuesday, November 10 the stock rating was initiated by JMP Securities with “Market Perform”. On Tuesday, September 5 the stock rating was upgraded by Wood to “Market Perform”. The firm earned “Buy” rating on Thursday, February 11 by Janney Capital. The stock has “Hold” rating by Keefe Bruyette & Woods on Wednesday, February 7. Keefe Bruyette & Woods maintained the stock with “Sell” rating in Friday, May 26 report. See Horace Mann Educators Corporation (NYSE:HMN) latest ratings:

07/02/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $43.0 Maintain

Investors sentiment decreased to 1 in 2018 Q1. Its down 0.02, from 1.02 in 2017Q4. It worsened, as 15 investors sold Keryx Biopharmaceuticals, Inc. shares while 30 reduced holdings. 17 funds opened positions while 28 raised stakes. 73.25 million shares or 2.09% less from 74.81 million shares in 2017Q4 were reported. Barclays Public Ltd reported 43,141 shares. Blackrock accumulated 6.08 million shares. Oppenheimer & Incorporated reported 64,238 shares stake. Raymond James Assocs owns 12,171 shares. Hl Finance Svcs Limited Liability Corp, Kentucky-based fund reported 23,000 shares. Rhenman & Ptnrs Asset Mngmt owns 302,157 shares for 0.15% of their portfolio. Swiss Bankshares holds 0% or 160,600 shares. Clearbridge Limited Co invested in 0% or 4,269 shares. Rhumbline Advisers has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Royal Bancorp Of Canada reported 3,654 shares. Bnp Paribas Arbitrage Sa has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Legal & General Grp Public Lc invested in 24,580 shares or 0% of the stock. New York-based Shufro Rose And Com Limited Liability Corporation has invested 0.03% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Chicago Equity Prtn Ltd Com has 198,730 shares. Marco Invest Management Ltd Company holds 48,350 shares.

Since January 5, 2018, it had 0 buys, and 20 insider sales for $310,689 activity. 9,048 shares were sold by Carberry Christine A., worth $44,064. The insider Neylan John F. sold $5,099. Madison Greg had sold 1,067 shares worth $5,004 on Friday, January 5. The insider Cameron Kevin J sold $8,702. $27,181 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares were sold by Holmes Scott A. Shares for $7,412 were sold by Adams Brian on Monday, January 29. GILMAN STEVEN C sold 1,334 shares worth $6,830.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on July, 26. They expect $-0.16 EPS, up 23.81% or $0.05 from last year’s $-0.21 per share. After $-0.18 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.72’s average target is 71.65% above currents $5.08 stock price. Keryx Biopharmaceuticals had 37 analyst reports since July 23, 2015 according to SRatingsIntel. As per Thursday, July 27, the company rating was maintained by Cowen & Co. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Market Perform” rating given on Thursday, July 23 by Cowen & Co. Morgan Stanley maintained it with “Equal-Weight” rating and $7 target in Tuesday, July 25 report. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Buy” rating given on Thursday, July 27 by Maxim Group. Ladenburg Thalmann maintained it with “Buy” rating and $9 target in Tuesday, August 2 report. The firm has “Buy” rating by Maxim Group given on Tuesday, March 29. The firm earned “Mkt Perform” rating on Tuesday, August 11 by FBR Capital. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, February 8. As per Thursday, July 23, the company rating was maintained by TH Capital. The firm has “Buy” rating by Maxim Group given on Thursday, July 20.

Since March 6, 2018, it had 0 insider purchases, and 6 sales for $1.44 million activity. 4,259 Horace Mann Educators Corporation (NYSE:HMN) shares with value of $190,875 were sold by CONKLIN BRET A. On Friday, June 1 Hassenmiller Steve sold $133,200 worth of Horace Mann Educators Corporation (NYSE:HMN) or 3,000 shares. On Friday, June 1 the insider Sharpe Matthew P. sold $448,016. The insider Stricker Robert sold $113,923. $429,549 worth of stock was sold by Caldwell William J. on Thursday, May 31.

Investors sentiment increased to 1.36 in 2018 Q1. Its up 0.11, from 1.25 in 2017Q4. It is positive, as 11 investors sold Horace Mann Educators Corporation shares while 53 reduced holdings. 23 funds opened positions while 64 raised stakes. 39.05 million shares or 2.16% less from 39.92 million shares in 2017Q4 were reported. Credit Suisse Ag invested 0% of its portfolio in Horace Mann Educators Corporation (NYSE:HMN). 8,016 are held by Qs Invsts Limited Liability Co. State Of Alaska Department Of Revenue holds 0.01% or 13,166 shares. Bridgeway Capital Mngmt holds 0.09% of its portfolio in Horace Mann Educators Corporation (NYSE:HMN) for 199,550 shares. Suntrust Banks holds 0.02% in Horace Mann Educators Corporation (NYSE:HMN) or 63,079 shares. Brandywine Inv Mgmt Ltd Company reported 130,999 shares stake. Swiss Bancshares invested in 70,900 shares or 0% of the stock. Dean Invest Limited Liability reported 89,605 shares. Texas Permanent School Fund has invested 0.02% in Horace Mann Educators Corporation (NYSE:HMN). Fdx Advsr has 0.01% invested in Horace Mann Educators Corporation (NYSE:HMN) for 6,001 shares. Royal Fincl Bank Of Canada has 0% invested in Horace Mann Educators Corporation (NYSE:HMN) for 15,826 shares. Segall Bryant & Hamill Ltd Llc reported 5,687 shares. Legal & General Group Public Ltd Liability Com stated it has 85,579 shares or 0% of all its holdings. Punch & Associate Invest has invested 0.67% in Horace Mann Educators Corporation (NYSE:HMN). Aperio Limited Liability Corp has 27,772 shares for 0.01% of their portfolio.

Another recent and important Horace Mann Educators Corporation (NYSE:HMN) news was published by Businesswire.com which published an article titled: “AM Best Affirms Credit Ratings of Horace Mann Educators Corporation and Its Subsidiaries” on May 23, 2018.

The stock decreased 0.59% or $0.26 during the last trading session, reaching $44.4. About 85,097 shares traded. Horace Mann Educators Corporation (NYSE:HMN) has risen 15.36% since June 14, 2017 and is uptrending. It has outperformed by 2.79% the S&P500. Some Historical HMN News: ; 07/03/2018 – Horace Mann Educators Raises Dividend to 28.5c Vs. 27.5c; 07/03/2018 Horace Mann Increases Quarterly Dividend by 3.6%; 10/04/2018 – Horace and Amy Hagedorn Fund establishes Northwell Health Visits Program and Scholarship Fund to support Hofstra Northwell School of Graduate Nursing; 02/05/2018 – HORACE MANN 1Q REV. $295.5M; 04/05/2018 – Horace Mann Closes Above 50-Day Moving Average: Technicals; 08/03/2018 – Horace Mann Chairman To Retire After 8 Years In The Role — MarketWatch; 02/05/2018 – HORACE MANN 1Q OPER EPS 51C, EST. 63C; 13/03/2018 – HORACE MANN EDUCATORS FILES MIXED SECURITIES SHELF; 08/03/2018 – Horace Mann Educators: Shaheen Won’t Stand for Re-election to Board at May 23 Meeting; 23/05/2018 – A.M. Best Affirms Credit Ratings of Horace Mann Educators Corporation and Its Subsidiaries

Horace Mann Educators Corporation, through its subsidiaries, operates as a multiline insurance firm in the United States. The company has market cap of $1.82 billion. The Firm operates through four divisions: Property and Casualty Insurance, Annuity Products, Life Insurance, and Corporate and Other. It has a 10.88 P/E ratio. It underwrites and markets personal lines of property and casualty insurance, including personal lines automobile and homeowners insurance products; retirement products, such as tax-qualified annuities; and life insurance products.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Institutional Positions Chart